Concordance among four commercially available, validated programmed cell death ligand-1 assays in urothelial carcinoma

Table 2 OPA, PPA, and NPA between PD-L1 assays

Clinical algorithm	Comparator assay	VENTANA SP263 (TC/IC 25%) assay used as reference, % agreement (95% CI) ^a
Clinical algorithm	Comparator assay	OPA	PPA	NPA
TC or IC_ICArea ≥ 25% (VENTANA SP263)	PD-L1 IHC 22C3 pharmDx	92.2% (89.4%)	86.4% (80.1%)	95.4% (92.3%)
	PD-L1 IHC 28–8 pharmDx	90.7% (87.7%)	79.7% (72.6%)	96.8% (94.0%)
	VENTANA SP142	85.7% (82.1%)	64.4% (56.5%)	97.2% (94.6%)
CPS ≥1 (PD-L1 IHC 22C3 pharmDx)	PD-L1 IHC 22C3 pharmDx	77.0% (72.9%)	90.7% (85.0%)	69.6% (64.0%)
CPS ≥10 (PD-L1 IHC 22C3 pharmDx)	PD-L1 IHC 22C3 pharmDx	81.5% (77.6%)	62.7% (54.8%)	91.7% (87.9%)
TC ≥1% (PD-L1 IHC 28–8 pharmDx)	PD-L1 IHC 28–8 pharmDx	75.5% (71.3%)	66.9% (59.1%)	80.2% (75.2%)
IC_TumorArea ≥ 5% (VENTANA SP142)	VENTANA SP142	69.9% (65.5%)	15.3% (10.1%)	99.5% (97.8%)

^a For each metric, lower boundary of 95% confidence interval (CI) was calculated with no upper bound using the Clopper–Pearson method [37]
CPS combined positive score, IC immune cell, IHC immunohistochemistry, NPA negative percentage agreement, OPA overall percentage agreement, PD-L1 programmed cell death ligand-1, PPA positive percentage agreement, TC tumor cell

ISSN: 1746-1596